Epigral Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/foz274tuv6xxqx80zfxc57cu.pdf

Key Takeaways


Volume Growth & Product Mix Shift

Maulik Patel: "we are going to add further 75,000 tons per annum in CPVC resin to reach the total capacity of 150,000 tons per annum, and it will be the largest capacity plant in the world."

Chlor-Alkali & ECU Dynamics

Maulik Patel: "the caustic soda is... driven by the caustic soda because of lack of propylene in India... definitely demand of caustic is going to go up and the chlorine derivative people need to find a way to utilize the chlorine internally."

Expansion Projects & Timelines


CPVC: Technology Moat & Pricing Risk

Maulik Patel: "It is a very complex process. In terms of the engineering, it is very complex. In terms of the corrosiveness it is highly corrosive. And in terms of the customer also in the -- in terms of application, you need to have a lot of infrastructure in terms of the application also. So it is not that easy to manufacture."

Chlorotoluene & ECH: Domestic Market Build-Out


Margins, Costs & Guidance

Milind Kotecha: "first half we have done 28% kind of margin. And we said in a normal situation, we can be in the range of around 25% to 27%. But when I say 25%, it is for this year, it is for next year. So we are putting it that way."

Guidance & Commitments

CommitmentSpecificsTimeline
CPVC capacity expansion75,000 TPA added to reach 150,000 TPA totalCommission H1 FY27; optimal run FY28
ECH capacity expansion50,000 TPA added, largest in IndiaCommission H1 FY27; optimal run FY28
Chlorotoluene full commissioningAll blocks operationalQ4 FY25
Chlorotoluene volume ramp-upSmall initial orders, actual pick-upQ2 of next fiscal year
CPVC compound plant contributionSizable revenue contributionQ4 FY25 onwards
New value chain detailsDisclosure on import-substitute product for 100-acre landBy end of March
Full-year EBITDA margin25% (conservative guidance)FY25
Full-year revenue and PATINR2,500–2,600 crores revenue, INR300–350 crores PATFY25
External chlorine sales reductionFrom 21% currently to ~10%After CPVC and ECH project commissioning

Key Metrics

MetricQ2 FY25
Revenue₹632 cr, +32% YoY
EBITDA₹178 cr, +65% YoY
EBITDA margin29%, vs 23% in Q2 FY24
PAT₹81 cr, +111% YoY
PAT margin13%, vs 8% in Q2 FY24
Sales volume growth6% YoY, flat QoQ
Capacity utilization83%, vs 77% in Q2 FY24
Derivatives & Specialty revenue share59%, vs 46% in Q2 FY24 and 53% in Q1 FY25
Total debt₹895 cr as on 30 Sep 2024, vs ₹963 cr as on 31 Mar 2024
Net debt-to-EBITDA1.4x, vs 1.8x at end of Sep 2023
ROCE (trailing 12 months)24%, vs 21% as on 30 Sep 2023; 28% excluding capital work in progress
Caustic utilization~75%
ECH utilization~85%
CPVC utilization65–70%
Chlorine captive consumption79%, up from 70% in Q2; 21% sold in market
ECU realization~₹26,000 in Q2; moved to ~₹30,000–31,000 post quarter-end
Full-year EBITDA margin guidance24–25% (conservative); H1 FY25 at 28%